Compare
BioMarin Pharmaceutical Inc vs United Therapeutics Corp vs Alnylam Pharmaceuticals, Inc. vs Perrigo Co PLC
| Latest fiscal year | BioMarin Pharmaceutical Inc BMRN | United Therapeutics Corp UTHR | Alnylam Pharmaceuticals, Inc. ALNY | Perrigo Co PLC PRGO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.22B | $3.18B | $3.71B | $4.25B |
| Revenue growth (YoY) | +12.9% | +10.6% | +65.2% | -2.8% |
| Gross margin | 77.7% (computed) | 87.9% (computed) | 81.8% (computed) | 35.1% |
| Operating margin | 12.7% | 46.9% | 13.5% | -26.4% |
| Net margin | 10.8% | 41.9% | 8.4% | -33.5% |
| Net income | $348.90M | $1.33B | $313.75M | -$1.43B |
| EPS (Diluted) | $1.80 | $27.86 | $2.33 | -$10.29 |
| Operating cash flow | $827.99M | $1.56B | $524.08M | $238.50M |
| Free cash flow | $724.96M | $1.04B | $465.38M | $145.10M |
| Cash & equivalents | $1.31B | $1.56B | $1.66B | n/a |
| Total assets | $7.59B | $7.88B | $4.97B | $8.54B |
| Total liabilities | $1.51B | $783.80M | $4.18B | $5.60B |
| Shareholders' equity | $6.09B | $7.10B | $789.18M | $2.94B |
| Return on year-end equity | 5.7% | 18.8% | 39.8% | -48.6% |
| Shares outstanding | 192.30M | 43.64M | 132.38M | 137.60M |
Revenue, most recent five fiscal years
| Fiscal year | BioMarin Pharmaceutical Inc | United Therapeutics Corp | Alnylam Pharmaceuticals, Inc. | Perrigo Co PLC |
|---|---|---|---|---|
| Latest | $3.22B Ended 2025-12-31 | $3.18B Ended 2025-12-31 | $3.71B Ended 2025-12-31 | $4.25B Ended 2025-12-31 |
| 1 year earlier | $2.85B Ended 2024-12-31 | $2.88B Ended 2024-12-31 | $2.25B Ended 2024-12-31 | $4.37B Ended 2024-12-31 |
| 2 years earlier | $2.42B Ended 2023-12-31 | $2.33B Ended 2023-12-31 | $1.83B Ended 2023-12-31 | $4.66B Ended 2023-12-31 |
| 3 years earlier | $2.10B Ended 2022-12-31 | $1.94B Ended 2022-12-31 | $1.04B Ended 2022-12-31 | $4.45B Ended 2022-12-31 |
| 4 years earlier | $1.85B Ended 2021-12-31 | $1.69B Ended 2021-12-31 | $844.29M Ended 2021-12-31 | $4.14B Ended 2021-12-31 |